Use of Ziv Aflibercept in Different Retinal Diseases

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

Bağlantı panoya saxlanılır

StatusTamamlandı

Sponsorlar

Amin El Sayed Nawar

Əməkdaşlar

Tanta University

KLINIK SINAQ: NCT04290195

BioSeek: nct04290195

Açar sözlər

Mücərrəd

A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were carried out under the tenets of the Helsinki Declaration. Written consent was provided by all participants after discussing the procedure, alternative treatment plans, follow-up schedules, and possible benefits and risks.

Təsvir

Intravitreal injection of 1.25 mg of ziv aflibercept was done in different retinal diseases including myopic CVN,resistant diabetic macular edema to previous ranibizumab injection and non ischaemic CRVO .Thorough ophthalmic evaluation was done including BCVA(best corrected visual acuity) ,anterior and posterior segment examination ,fundus fluorescein angiography and OCT(optical coherence tomography) were performed for all patients .Injection was repeated as PRN(pro re nata) method after one month if persistent intraretinal or subretinal fluid was found.

Tarixlər

Son Doğrulandı:	01/31/2020
İlk təqdim:	02/22/2020
Təxmini qeydiyyat təqdim edildi:	02/25/2020
İlk Göndərmə:	02/27/2020
Son Yeniləmə Göndərildi:	02/25/2020
Son Yeniləmə Göndərildi:	02/27/2020
Həqiqi Təhsilin Başlama Tarixi:	05/31/2019
Təxmini İlkin Tamamlanma Tarixi:	11/30/2019
Təxmini İşin Tamamlanma Tarixi:	12/31/2019

Vəziyyət və ya xəstəlik

Central Retinal Vein Occlusion With Macular Edema

Müdaxilə / müalicə

Drug: ziv aflibercept patients

Faza

Faza 1/Faza 2

Qol Qrupları

Qol	Müdaxilə / müalicə
Experimental: ziv aflibercept patients 20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO	Drug: ziv aflibercept patients Intravitreal injection of 1.25 mg of ziv aflibercept in patients

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar	31 Years Üçün 31 Years
Təhsilə Uyğun Cinslər	All
Sağlam Könüllüləri qəbul edir	Bəli
Kriteriyalar	Inclusion Criteria: - The study included treatment naive patients suffering from recently diagnosed active myopic subfoveal or juxtafoveal CNV less than 2 months documented by fundus fluorescein angiography (FFA)and optical coherence tomography (OCT ) , pathological myopia more than 6 D was included . Exclusion Criteria: - Previous intraocular surgery . - Coincident retinal pathology as diabetic retinopathy, retinal vein occlusion . - CNV due to other causes like age related macular degeneration ,angioid streaks,trauma and choroiditis. - Extrafoveal myopic CNV . - Patients received other lines of treatment for CNV like photodynamic therapy ,laser photocoagulation or intravitreal injection of triamcinolone or other anti VEGF(vascular endothelial growth factor) agents. - Known glaucoma , clinical suspicion of glaucoma or IOP(intraocular pressure) more than 20 mmHg. - Prior ocular inflammation. - The presence of retinal degeneration. - Patients who didnot complete 6 months of follow up

Nəticə

İlkin nəticə tədbirləri

1. Improvement of BCVA by log MAR(minimum angle of resolution) and reduction of CMT after intravitreal injection [6 months]

To assess if there is improvement of BCVA(Best corrected visual acuity) and reduction of the CMT (central macular thickness) after intravitreal injection of zivaflibercept